Published online before print June 17, 2002, doi: 10.1161/01.CIR.0000021599.56755.A1
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:191.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
Efficacy Assessment of Meloxicam, a Preferential Cyclooxygenase-2 Inhibitor, in Acute Coronary Syndromes Without ST-Segment Elevation
The Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) Pilot Study
From the Centro de Trombosis de Buenos Aires, Catedra de Magister en Trombosis, Facultad de Medicina de Tucuman and Department of Pharmacology (C.G.), Facultad de Medicina de Buenos Aires, Argentina.
Correspondence to Raul Altman, MD, PhD, Centro de Trombosis de Buenos Aires, Viamonte 2008, 1056 Buenos Aires, Argentina. E-mail draltman{at}arnet.com.ar
Background— Despite the use of heparin, aspirin, and other antiplatelet agents, acute coronary syndrome patients without ST-segment elevation remain at risk of cardiovascular thrombotic events. Given the role of inflammation in the pathogenesis of arterial thrombosis, we tested the hypothesis that the combination of meloxicam, a preferential COX-2 inhibitor, and heparin and aspirin would be superior to heparin and aspirin alone.
Methods and Results— In an open-label, randomized, prospective, single-blind pilot study, patients with acute coronary syndromes without ST-segment elevation were randomized to aspirin and heparin treatment (n=60) or aspirin, heparin, and meloxicam (n=60) during coronary care unit stay. Patients then received aspirin or aspirin plus meloxicam for 30 days. During the coronary care unit stay, the primary outcomes variable of recurrent angina, myocardial infarction, or death was significantly lower in the patients receiving meloxicam (15.0% versus 38.3%, P=0.007). The second composite variable (coronary revascularization procedures, myocardial infarction, and death) was also significantly lower in meloxicam-treated patients (10.0% versus 26.7%, P=0.034). At 90 days, the primary end point remained significantly lower in the meloxicam group (21.7% versus 48.3%, P=0.004), as did the secondary end point (13.3% versus 33.3%, P=0.015) and the need for revascularization alone (11.7% versus 30.0%, P=0.025). No adverse complications associated with the meloxicam treatment were observed.
Conclusions— Meloxicam with heparin and aspirin was associated with significant reductions in adverse outcomes in acute coronary syndrome patients without ST-segment elevation. Additional larger trials are required to confirm the findings of this pilot study.
Key Words: inflammation • coronary disease • thrombosis • aspirin
This article has been cited by other articles:
 |
|
 |
|
  C. de Diego, R. K. Pai, A. S. Dave, A. Lynch, M. Thu, F. Chen, L.-H. Xie, J. N. Weiss, and M. Valderrabano Spatially discordant alternans in cardiomyocyte monolayers Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1417 - H1425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mahajan, Y. Shiferaw, D. Sato, A. Baher, R. Olcese, L.-H. Xie, M.-J. Yang, P.-S. Chen, J. G. Restrepo, A. Karma, et al. A Rabbit Ventricular Action Potential Model Replicating Cardiac Dynamics at Rapid Heart Rates Biophys. J., January 15, 2008; 94(2): 392 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Qu and J. N. Weiss The chicken or the egg? Voltage and calcium dynamics in the heart Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2054 - H2055. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Salinas, U. C. Rangasetty, B. F. Uretsky, and Y. Birnbaum The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 98 - 111. [Abstract] [PDF]
|
|
|
|
 |
|
 M E Farkouh, J D Greenberg, R V Jeger, K Ramanathan, F W A Verheugt, J H Chesebro, H Kirshner, J S Hochman, C L Lay, S Ruland, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib Ann Rheum Dis, June 1, 2007; 66(6): 764 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Bata, M. Al-Ramahi, A. S. Salhab, M. N. Gharaibeh, and J. Schwartz Delay of Ovulation by Meloxicam in Healthy Cycling Volunteers: A Placebo-Controlled, Double-blind, Crossover Study. J. Clin. Pharmacol., August 1, 2006; 46(8): 925 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Weiss, A. Karma, Y. Shiferaw, P.-S. Chen, A. Garfinkel, and Z. Qu From Pulsus to Pulseless: The Saga of Cardiac Alternans Circ. Res., May 26, 2006; 98(10): 1244 - 1253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Rizzello, G. Liuzzo, S. Brugaletta, A. Rebuzzi, L. M. Biasucci, and F. Crea Modulation of CD4+CD28null T Lymphocytes by Tumor Necrosis Factor-{alpha} Blockade in Patients With Unstable Angina Circulation, May 16, 2006; 113(19): 2272 - 2277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bishop-Bailey, J. A. Mitchell, and T. D. Warner COX-2 in cardiovascular disease. Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 956 - 958. [Full Text] [PDF]
|
|
|
|
|
|
Z. Qu Critical mass hypothesis revisited: role of dynamical wave stability in spontaneous termination of cardiac fibrillation Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H255 - H263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Qu and J. N. Weiss Effects of Na+ and K+ channel blockade on vulnerability to and termination of fibrillation in simulated normal cardiac tissue Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1692 - H1701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Kimmel, J. A. Berlin, M. Reilly, J. Jaskowiak, L. Kishel, J. Chittams, and B. L. Strom Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction Ann Intern Med, February 1, 2005; 142(3): 157 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Finckh and M. D. Aronson Cardiovascular Risks of Cyclooxygenase-2 Inhibitors: Where We Stand Now Ann Intern Med, February 1, 2005; 142(3): 212 - 214. [Full Text] [PDF]
|
|
|
|
|
|
Z. Qu Dynamical effects of diffusive cell coupling on cardiac excitation and propagation: a simulation study Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2803 - H2812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bogaty, J. M. Brophy, M. Noel, L. Boyer, S. Simard, F. Bertrand, and G. R. Dagenais Impact of Prolonged Cyclooxygenase-2 Inhibition on Inflammatory Markers and Endothelial Function in Patients With Ischemic Heart Disease and Raised C-Reactive Protein: A Randomized Placebo-Controlled Study Circulation, August 24, 2004; 110(8): 934 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Willerson and P. M. Ridker Inflammation as a Cardiovascular Risk Factor Circulation, June 1, 2004; 109(21_suppl_1): II-2 - II-10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. WARNER and J. A. MITCHELL Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic FASEB J, May 1, 2004; 18(7): 790 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Monakier, M. Mates, M. W. Klutstein, J. A. Balkin, B. Rudensky, D. Meerkin, and D. Tzivoni Rofecoxib, a COX-2 Inhibitor, Lowers C-Reactive Protein and Interleukin-6 Levels in Patients With Acute Coronary Syndromes Chest, May 1, 2004; 125(5): 1610 - 1615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Dai and R. A. Kloner Relationship Between Cyclooxygenase-2 Inhibition and Thrombogenesis Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1): 51 - 59. [Abstract] [PDF]
|
|
|
|
 |
|
 P. A. Howard and P. Delafontaine Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk J. Am. Coll. Cardiol., February 18, 2004; 43(4): 519 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Title, K. Giddens, M. M. McInerney, M. J. McQueen, and B. A. Nassar Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1747 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Verma and P. E. Szmitko Coxibs and the endothelium J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1754 - 1756. [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Hankey and J. W. Eikelboom Cyclooxygenase-2 Inhibitors: Are They Really Atherothrombotic, and If Not, Why Not? Stroke, November 1, 2003; 34(11): 2736 - 2740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Nair, H. Bartsch, and J. Nair Prevention of degenerative diseases; clues from studies investigating oxidative stress, Brussels, 13 November 2002 Mutagenesis, September 1, 2003; 18(5): 477 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Widlansky, D. T. Price, N. Gokce, R. T. Eberhardt, S. J. Duffy, M. Holbrook, C. Maxwell, J. Palmisano, J. F. Keaney Jr, J. D. Morrow, et al. Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension Hypertension, September 1, 2003; 42(3): 310 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Tuleja, F. Mejza, A. Cmiel, and A. Szczeklik Effects of Cyclooxygenases Inhibitors on Vasoactive Prostanoids and Thrombin Generation at the Site of Microvascular Injury in Healthy Men Arterioscler. Thromb. Vasc. Biol., June 1, 2003; 23(6): 1111 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Rezkalla and M. Benz Antiplatelet Therapy from Clinical Trials to Clinical Practice Clin. Med. Res., April 1, 2003; 1(2): 101 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chenevard, D. Hurlimann, M. Bechir, F. Enseleit, L. Spieker, M. Hermann, W. Riesen, S. Gay, R. E. Gay, M. Neidhart, et al. Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease Circulation, January 28, 2003; 107(3): 405 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 COX-2 Inhibitor May Stabilize Ruptured Plaques Journal Watch Emergency Medicine, October 29, 2002; 2002(1029): 6 - 6. [Full Text]
|
|
|
|
|
|
B. Pitt, C. Pepine, and J. T. Willerson Cyclooxygenase-2 Inhibition and Cardiovascular Events Circulation, July 9, 2002; 106(2): 167 - 169. [Full Text] [PDF]
|
|